April 9 (Reuters) - Humanigen Inc :
   * HUMANIGEN ANNOUNCES POSITIVE RESULTS FROM PHASE 1 STUDY OF IFABOTUZUMAB IN GLIOBLASTOMA MULTIFORME
   * HUMANIGEN INC - PHASE 1 DOSE ESCALATION AND BIOIMAGING STUDY SHOWS THAT IFABOTUZUMAB DEMONSTRATES HIGHLY SPECIFIC TUMOR TARGETING IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME

Source text for Eikon:  Further company coverage:

((Reuters.Briefs@thomsonreuters.com;)